Poor Science; Poorly Trained Scientists; Poor Policies: Major Deterrents to the War on Cancer
DOI:
https://doi.org/10.6000/1929-2279.2018.07.03.3Keywords:
Cancer, NIH policies, training of scientists, excessive molecular biology, holistic physiological/pathophysiological approach.Abstract
Although the availability of funding has been described as the major limitation on advances in cancer, the progress in the war on cancer has been deterred mainly by poor science, poorly trained scientists, and poor NIH policies. This is the result of NIH policies of its extreme focus on molecular biology (genomics, molecular genetics, molecular biology) identification of the molecular factors and pathways; which are required for the acceptability of treatment and preventive protocols. As such, this has influenced virtually all agencies that provide grants for medical research to adopt the NIH policies. This has impacted the funding of the research as well as the focus of the training of scientists. Directors of NCI Dr. Varmus (also Nobel Prize awardee) and Dr. Zerhouni had addressed this issue; and they rejected the necessity of molecular biology studies and information. NIH should return to the holistic physiological/pathophysiological approach to studies of cancer issues. This would provide the best approach for winning the war on cancer.
References
Zerhouni E. The NIH roadmap. Science 2003; 332: 63-5. https://doi.org/10.1126/science.1091867
Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004; 149(6): 76-82.
Costello LC. The effect of contemporary education and training of biomedical scientists on present and future medical research. Acad Med 2009; 84: 459-63. https://doi.org/10.1097/ACM.0b013e31819a7c6b
Perspective: Is NIH funding the "best science by the best scientists"? A critique of the NIH R01 research grant review policies. Acad Med 2010; 85(5): 775-9. https://doi.org/10.1097/ACM.0b013e3181d74256
National Institutes of Health. Enhancing Peer Review at NIH: Overview. Available at: http://enhancing-peer-review.nih.gov/index.html. Accessed January 18, 2010
Office of Extramural Research, National Institutes of Health. Encouraging Early Transition to Research Independence: Modifying the NIH New Investigator Policy to Identify Early Stage Investigators. Available at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-121.html. Accessed January 18, 2010.
Bernard C. An Introduction to the Study of Experimental Medicine. New York, NY: The Macmillan Company 1927.
Downloads
Published
Issue
Section
How to Cite
Similar Articles
- Praneet Singh Bedi, Meenu Walia, Vipulkumar Thummar, Priya Mehta, A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting , Journal of Cancer Research Updates: Vol. 12 (2023)
- T. Akshaya, T. Senthil Kumar, R. Yogeshwari, S. Sridevi, N. Venkatesh, Chemotherapy-Induced Changes in Body Composition among Breast Cancer Patients: A Scoping Review , Journal of Cancer Research Updates: Vol. 14 (2025)
- Xingcai Zhang, Tea and Cancer Prevention , Journal of Cancer Research Updates: Vol. 4 No. 2 (2015): Special Issue - Natural Products for Cancer Prevention and Treatment
- Hua-Qing Chen, Yi-Si Li, Si-Chao Huang, Ya-Hua Lin, Qiu-Tong Tan, Shu-Ting Ao, Jun Xu, Shao-Hui Cai, The Clinical Efficacy and Safety of Paclitaxel in Adjuvant Therapy of Breast Cancer: A Systematic Review and Meta-Analysis , Journal of Cancer Research Updates: Vol. 4 No. 2 (2015): Special Issue - Natural Products for Cancer Prevention and Treatment
- Mario M. Soldevilla, Susana Inogés, Ascensión López-Díaz de Cerio, Fernando Pastor, Helena Villanueva, Maurizio Bendandi, Biological Efficacy of a Dendritic Cell-Based Vaccine in a Patient with Metastatic Colorectal Cancer , Journal of Cancer Research Updates: Vol. 1 No. 1 (2012)
- Naveen Karuvandan, Pradeep Ventrapati, Real-World Clinical Outcomes of Ujvira® (Trastuzumab Emtansine Biosimilar) in HER2-Positive Breast Cancer: A Retrospective Observational Study in Indian Patients , Journal of Cancer Research Updates: Vol. 14 (2025)
- Nikhil Vasdev, Patricia McClurey, Debra Gray, Aftab Bhatti, David Chadwick, An Audit to Evaluate the Clinical Safety and PSA Response of Firmagon® (Degarelix) in Patients with Advanced Metastatic Prostate Cancer - , Journal of Cancer Research Updates: Vol. 2 No. 1 (2013)
- Kevan B. Tucker, Kristina L. Makey, Edmund Chinchar, Min Huang, Natale Sheehan, Srinivasan Vijayakumar, Jian-Wei Gu, EGCG Suppresses Melanoma Tumor Angiogenesis and Growth without Affecting Angiogenesis and VEGF Expression in the Heart and Skeletal Muscles in Mice , Journal of Cancer Research Updates: Vol. 3 No. 1 (2014)
- Shaimaa A. Soliman, Laila A. Rashed, Mahmoud M. Said, Amina M. Medhat, Assessment of Gene Expression Level of ATP Binding Cassette G Member 2 (ABCG2) Transporter in Newly Diagnosed Breast Cancer Patients Receiving Adjuvant Chemotherapy , Journal of Cancer Research Updates: Vol. 8 No. 1 (2019)
- Ciro Comparetto, Franco Borruto, Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology , Journal of Cancer Research Updates: Vol. 9 No. 1 (2020)
You may also start an advanced similarity search for this article.